Project Grant K01CA279492
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$162K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award of $315,143.00 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports clinical trial research in the oncology landscape. The award, which has an ultimate completion date of August 31, 2029, is being provided to The Ohio State University, a leading public research university. Through this funding, The Ohio State University will conduct innovative cancer research focused on understanding cancer mechanisms, developing new diagnostic and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,062 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the biological mechanisms contributing to racial disparities in head and neck cancer outcomes, particularly among Black patients. The key objectives are to: 1) Develop a prognostic model using gene expression signatures to predict disease progression in early-stage oral squamous cell...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...
This $656,014 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a randomized clinical trial at The Ohio State University to evaluate the effectiveness of a telemedicine-mHealth symptom management intervention, called FOCUS, for advanced cancer patients in underserved rural communities. The FOCUS intervention aims to improve a symptom cluster including sleep difficulties, anxiety, depression, and fatigue, and enhance functional...
The National Cancer Institute (NCI) awarded a $168,500 Project Grant under the "Cancer Cause and Prevention Research" (CFDA 93.393) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The two-year grant, with an ultimate completion date of July 31, 2025, aims to evaluate physical and mental health symptoms (patient-reported outcomes) throughout the cancer diagnosis trajectory and their associations with cancer outcomes among HIV-positive...
The National Cancer Institute (NCI) awarded a $432,304 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, awarded on January 3, 2025, supports a 5-year research project focused on "Enhanced Cancer Risk Predictions in Underrepresented Populations through Robust Multi-Source Data Integration." The project aims to develop novel data integration methods to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Emory University provides $659,498.00 to conduct research on racial disparities in the mechanisms of prostate cancer metastasis. The project aims to analyze differential pathway activity, particularly involving the FGFR3 signaling and oxidative phosphorylation (OXPHOS) pathways, and their impact on metastasis in African American prostate cancer patients. The research will utilize in vitro and...
The Defense Health Agency awarded a $468,672 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Georgia College & State University. The grant, titled "The Inclusive Cancer Care Research Equity (ICCARE) for Black Men Consortium," will fund research focused on examining health-seeking behaviors, decision-making, psychosocial effects, and coping mechanisms among Black men with prostate cancer. The project will also test the efficacy of...
This $132,015 Project Grant award was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to The Ohio State University. The funding will support efforts to improve enrollment in clinical trials for gynecologic cancers, especially among underrepresented populations. Key activities include: Developing a comprehensive system at The Ohio State University Comprehensive Cancer Center to streamline molecular matching and identification of patients for...
This $1,073,982 National Cancer Institute project grant will fund research at Washington University in University City, Missouri from January 2023 through December 2027 under the Cancer Cause and Prevention Research program (CFDA 93.393). The research aims to document unmet social needs among 300 patient-caregiver dyads where the patient has breast or gynecologic cancer. It will analyze how social needs affect biopsychosocial outcomes for patients and caregivers, including depressive symptoms,...